Table 2.
Clinical information of patients who participated in the Solomon Islands national tuberculosis patient cost survey: 2017–2019
| Clinical characteristics | Extra-pulmonary TB N = 36 n (%) |
Pulmonary TB N = 147 n (%) |
All patients N = 183 n (%) |
p value* |
|---|---|---|---|---|
| Treatment registration group | ||||
| New | 34 (94.4) | 136 (92.5) | 170 (92.9) | 0.917 |
| Relapse | 1 (2.8) | 5 (3.4) | 6 (3.3) | |
| Retreatment excluding relapse | 1 (2.8) | 6 (4.1) | 7 (3.8) | |
| Drug resistance status | ||||
| Drug susceptible-TB | 36 (100.0) | 147 (100.0) | 183 (100.0) | – |
| HIV status | ||||
| Negative | 24 (66.7) | 92 (62.6) | 116 (63.4) | 0.813 |
| Positive | 0 (0.0) | 1 (0.7) | 1 (0.5) | |
| Unknown | 12 (33.3) | 54 (36.7) | 66 (36.1) | |
| Drug susceptibility testing conducted | ||||
| DST done | 0 (0.0) | 2 (1.4) | 2 (1.1) | 0.482 |
| DST not done | 36 (100.0) | 145 (98.6) | 181 (98.9) | |
| Mode of TB diagnosis | ||||
| Bacteriologically confirmed | 5 (13.9) | 116 (78.9) | 121 (66.1) | < 0.001 |
| Clinically diagnosed | 31 (86.1) | 31 (21.1) | 62 (33.9) | |
| Treatment phase | ||||
| Intensive phase | 21 (58.3) | 76 (51.7) | 97 (53.0) | 0.475 |
| Continuation phase | 15 (41.7) | 71 (48.3) | 86 (47.0) | |
| Duration of intensive phase (months, mean (95% CI)) | 2.3 (2.0, 2.5) | 2.1 (2.0, 2.2) | 2.1 (2.1, 2.2) | 0.048 |
| Duration of continuation phase (months, mean (95% CI)) | 5.1 (4.8, 5.5) | 4.8 (4.6, 5.0) | 4.9 (4.7, 5.0) | 0.054 |
| Treatment facility | ||||
| Government primary health care facility | 4 (11.1) | 15 (10.2) | 19 (10.4) | 0.126 |
| Government hospital | 31 (86.1) | 105 (71.4) | 136 (74.3) | |
| Faith based health center or hospital | 0 (0.0) | 15 (10.2) | 15 (8.2) | |
| Other | 1 (2.8) | 12 (8.2) | 13 (7.1) | |
| Mode of supervision for TB treatment: intensive phase | ||||
| Hospitalized | 21 (100.0) | 72 (94.7) | 93 (95.9) | 0.562 |
| Self-administered | 0 (0.0) | 2 (2.6) | 2 (2.1) | |
| Unknown | 0 (0.0) | 2 (2.6) | 2 (2.1) | |
| Mode of supervision for TB treatment: continuation phase | ||||
| Hospitalized | 0 (0.0) | 2 (2.8) | 2 (2.3) | 0.609 |
| Self-administered | 13 (86.7) | 57 (80.3) | 70 (81.4) | |
| Community-based DOT | 1 (6.7) | 10 (14.1) | 11 (12.8) | |
| Facility-based DOT | 1 (6.7) | 1 (1.4) | 2 (2.3) | |
| Unknown | 0 (0.0) | 1 (1.4) | 1 (1.2) | |
| Currently hospitalized | ||||
| No | 15 (41.7) | 73 (49.7) | 88 (48.1) | 0.390 |
| Yes | 21 (58.3) | 74 (50.3) | 95 (51.9) | |
| Previously hospitalized in the current phase | ||||
| No | 30 (83.3) | 117 (79.6) | 147 (80.3) | 0.613 |
| Yes | 6 (16.7) | 30 (20.4) | 36 (19.7) | |
| Number of days hospitalized in the current phase, mean (95% CI) | 41.6 (33.6, 49.5) | 43.6 (39.6, 47.7) | 43.2 (39.7, 46.8) | 0.647 |
Abbreviations: DOT Directly observed therapy; DST Drug susceptibility testing; DS TB Drug susceptible TB; EPTB Extra pulmonary TB; PTB Pulmonary TB; TB Tuberculosis. * P values compare the proportions of patients with the characteristic of interest, in the pulmonary and extra-pulmonary groups